Mesothelial Neoplasm clinical trials
39 active trials name this condition. Describe your situation to see which ones look like a fit.
Refine by biomarker
By location
- SW-682 in Advanced Solid Tumors
- Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
- Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
- A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
- A 2-part Phase 1/2 Open-label Trial on ODM-212
- Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
- A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy
- A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
- Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
- A Study of VET3-TGI in Patients With Solid Tumors
- Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Stereotactic Magnetic Resonance Guided Radiation Therapy
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1
- Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
- Detection of Genetic Markers of Lung Cancer
- A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
- Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- Integrated Cancer Repository for Cancer Research
- Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
- Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
- Molecular Analysis of Thoracic Malignancies
- A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
- Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Mesothelial Neoplasm” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.